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Acetaminophen-induced S-nitrosylation and
S-sulfenylation signalling in 3D cultured
hepatocarcinoma cell spheroids†
Katarzyna Wojdyla,‡§a Krzysztof Wrzesinski,§b James Williamson,¶a Stephen J. Feyb
and Adelina Rogowska-Wrzesinska*a
Acetaminophen (APAP) is possibly the most widely used medication globally and yet little is known of its
molecular eﬀects at therapeutic doses. Using a novel approach, we have analysed the redox proteome of
the hepatocellular cell line HepG2/C3A treated with therapeutic doses of APAP and quantitated both indi-
vidual protein abundance and their reversible S-nitrosylation (SNO) and S-sulfenylation (SOH) modiﬁcations
by mass spectrometry. APAP treatment results in a late, transient increase in ATP production and a multi-
plicity of alterations in protein abundance and modiﬁcations. The majority of the diﬀerentially SNO or SOH
modiﬁed proteins are found in the endoplasmic reticulum and cytosol, suggesting that the source of reac-
tive species is there. The cellular response indicates: constraint of fatty acid metabolism; reduction in ribo-
some construction and protein synthesis (to conserve ATP); maintenance of glutathione levels (by increased
synthetic capacity); and an increased NADPH production (via the pentose phosphate pathway). This
response appears to be coordinated, directly or indirectly, by the canonical Wnt and Nrf2 signalling path-
ways. Combined with the known role of NAPQI, these studies suggest that the physiological and toxicologi-
cal responses form a continuum: therapeutic doses of APAP produce reactive species and NAPQI in the
cytoplasm but result in little permanent damage. The cell mounts a multifaceted response which minimises
disruption and repairs are eﬀected within a day or two. Higher doses of APAP lead to intensiﬁed reactive
species production, which increasingly disturbs mitochondrial function and eventually leads to cell death.
Introduction
Acetaminophen (N-acetyl-p-aminophenol, APAP, paraceta-
mol®) is a popular analgesic used worldwide by people of all
ages. Administered within the recommended doses it is safe
and causes only minimal side eﬀects. However, APAP poison-
ing accounts for about half of all cases of acute liver failure in
the USA and in Great Britain.1 Despite decades of extensive
research into the toxicity of APAP, very little is actually known
about the hepatocyte’s metabolic response to APAP treatment
at non-toxic (therapeutic) doses.
APAP is mainly metabolized in the liver by phase II conju-
gating enzymes to nontoxic products (acetaminophen-sulphate
or -glucuronide) or by the phase I cytochrome P450 family of
enzymes (specifically CYP2E1, CYP1A2, and CYP3A4). CYP2E1
in particular has been shown to generate the toxic N-acetyl-
p-benzoquinone imine (NAPQI), a reactive metabolite that
binds to cysteine residues in cellular proteins.2,3 Toxic doses of
APAP lead to saturation of the sulphate and glucuronide path-
ways and to an increased production of NAPQI. This leads to
glutathione (GSH) depletion, and the NAPQI is thought to
cause hepatotoxicity by forming acetaminophen–protein
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adducts.4 N-Acetylcysteine treatment can prevent or limit liver
injury by restoring hepatic GSH concentrations.4
Thus, while earlier research suggested that NAPQI and its
protein adducts gave rise to hepatotoxicity and that glutathione
(GSH) had a protective role, recent research has shown that
low levels of these products are formed even after administer-
ing therapeutic doses (4 g daily) to trial participants.5 At these
therapeutic APAP doses, cytosolic NADPH:quinone oxidoreduc-
tase 1 (NQO1) is strongly upregulated6 and detoxifies NAPQI
by reducing the quinone to hydroquinone (using NADPH in
the process).7 At the same time NAPQI is rapidly and irreversi-
bly conjugated with GSH.8 Currently, it is considered that
excess NAPQI–protein adducts cause mitochondrial oxidative
stress. Increasing levels of NAPQI stimulate reactive metabolite
formation (e.g. Reactive Oxygen Species, ROS), which induces
structural alterations in mitochondrial proteins and DNA.
At high stress levels this causes a loss of mitochondrial
membrane potential, cessation of ATP synthesis and an
initiation of cell death. The release of cytochrome C and other
proapoptotic factors promotes caspase activation and apopto-
tic cell death.9
In view of the role played by reactive metabolites, we ana-
lysed protein oxidation in order to probe deeper into the
eﬀects of APAP treatment. Superoxide (O2
•−) is a known by-
product of NAPQI metabolism. Its neutralisation by intracellu-
lar antioxidant systems leads to the formation of hydrogen per-
oxide (H2O2) and peroxynitrite (ONOO
−),9 both of which are
capable of modifying proteins. Cysteine thiols are highly sus-
ceptible to oxidation by these species and can form e.g. S-sulfe-
nic acid (SOH) and/or S-nitrosothiol (SNO).
SOH is predominantly generated by the spontaneous reac-
tion of cysteines with H2O2. SOH is highly reactive and short-
lived and may be irreversibly oxidised to sulfinic (SO2H) and
sulfonic acid (SO3H). Therefore SOH is a marker of oxidative
stress-related damage.10
SNO is formed by either the direct interaction of cysteines
with nitrogen species e.g. peroxynitrite or results from trans-
nitrosylation (the transfer of the nitroso group from S-nitro-
sylated small molecules or proteins). SNO modification can
alter enzyme activity and protein–protein interactions, mediate
protein localisation and alter protein stability.11
SNO and SOH are well recognised for their role in the regu-
lation of protein activity and protein–protein interaction and
thereby provide an additional avenue for intracellular signal-
ling.12 Therefore we have re-investigated the APAP mode of
action using a recently developed mass spectrometry-based
SNO/SOH TMT method.13 This approach enables site-specific
quantitation of SNO and SOH simultaneously, with concurrent
correction of modification levels by protein abundance
changes. The sensitivity of SNO/SOH TMT allows the detection
of endogenous oxidation levels of the individual proteins.13
Understanding the molecular response to APAP treatment
needs to be investigated in models relevant to human patho-
physiology. Cell lines derived from human hepatocellular carci-
nomas are an inexpensive and reproducible source of
essentially unlimited amounts of material for study. However,
HepG2 and its daughter strain HepG2/C3A (hereafter denoted
C3A) are generally regarded as poor models for
hepatotoxicology.14–16 This perception is based on the use of
cell culture techniques that disfavour the cellular expression of
functions seen in vivo. When grown as 3D spheroids, and
without using special media, growth factors or other chemicals
(e.g. DMSO), C3A restore, over an 18 day period, cholesterol,
urea, ATP, glycogen production and growth rates seen in vivo.17
Ramaiahgari et al. obtained very similar results using the
closely related HepG2 cell line cultivated in Matrigel under 3D
conditions, where they showed increased expression of
albumin, xenobiotic transcription factors, phase I and II drug
metabolism enzymes and transporters.18 The hepatic features
recovered by growing cells in various types of 3D culture
systems have been reviewed recently.19,20 These metabolic fea-
tures are stable for at least 24 days.17,18 C3A 3D spheroids
retain epigenetic markers that are seen in the liver but lost
when the C3A cells are cultivated under 2D conditions.21 This
recovery of physiological performance when grown in 3D is not
limited to HepG2 but is also seen with other cell lines, for
example, HepRG22 and many other cell types (reviewed in ref.
17 and 23). Most importantly, indirect comparison of LD50
values for in vitro and in vivo toxicity showed that data from
C3A spheroids correlated better with in vivo observations than
did studies using traditional two dimensional cultures of
primary human hepatocytes (for 5 commonly used drugs
including APAP).24
We hypothesise that the redox imbalance triggered by
APAP metabolism would alter levels of SNO and SOH protein
modifications. Many of these types of protein modifications
are transient and could be involved in rapidly regulating
the cellular non-hormonal intracrine signalling and response
to APAP.
Materials and methods
Materials
HepG2/C3A were obtained from American Type Culture Collec-
tion (cat. no. CRL10741, the third passage after receipt from
ATCC, Manassas, Virginia). D-MEM (1 g glucose per L), non-
essential amino acids, penicillin/streptomycin, GlutaMAX,
Trypsin/EDTA, and 0.4% trypan blue were all purchased from
Gibco (Carlsbad, California); AggreWell™ 400 plates (Stemcell
Technologies (Grenoble, France)) cell culture bioreactors (MC2
Biotek (Hørsholm, Denmark)), opaque microtitre plates (Nunc,
Roskilde, Denmark; cat. no. 165306), and CellTiter-Glo lumine-
scent cell viability assay (Promega, Fitchburg, WI). iodoTMT™
tags, immobilised and unbound anti-TMT™ antibody, Tris-
buﬀered saline (TBS), tris(2-carboxyethyl)phosphine (TCEP),
TMT-Elution Buﬀer, Pierce Screw Cup Spin Columns, Zeba
Spin desalting columns and BCA assay were from Thermo
Scientific. FCS (foetal calf serum), Acetaminophen (APAP) and
the remaining chemicals were from Sigma Aldrich. All solvents
were of analytical or higher grade.
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Methods
For all reagents, the final concentrations are reported, unless
stated otherwise. All steps from oxidation induction to quench-
ing after iodoTMT™ labelling were performed under minimal
light exposure.
3D cell culture
The C3A spheroids were prepared as previously described.17
Briefly, C3A cell spheroids were prepared using AggreWell™
400 plates (Stemcell Technologies cat. no. 27845). Spheroids
were cultured in microgravity bioreactors (MC2 Biotek,
Hørsholm, cat. no. 010), the humidity chamber was filled with
distilled sterile water, and the growth chamber was prewetted
with growth medium for 24 h before use by rotation in the
incubator. Bioreactors were turned at appropriate speeds using
the 16 axel BioArray Matrix drive BAM v4 (CelVivo, Blommen-
slyst). Spheroids were detached from the AggreWell™ plates,
visually selected, placed in the microgravity bioreactors and
cultivated in DMEM (1 g glucose per L) at 37 °C, 5% CO2, 95%
air for a minimum of 21 days, exchanging the medium every
two to three days.
APAP treatment
In vivo studies are usually defined by grams of the compound
per kilogram (kg) body weight of the organism. In the labora-
tory, since it would be diﬃcult to weigh the cells, a convenient
equivalent is milligrams of compound per milligram of total
soluble cellular protein present. Assuming that in a 70 kg
adult, the liver weighs 1.5 kg (ref. 25) and contains 0.5 kg
blood,26 then by assuming that 60% of the liver is hepatocytes
and that each cell contains 18% by weight protein,27 it is poss-
ible to calculate that the liver contains 108 g hepatocyte pro-
teins. Since the recommended dose for APAP is 4 g per day
and that 100% of the dose reaches the liver after
50 minutes,28,29 this gives a physiologically relevant dose of
0.03 mg APAP per mg hepatocyte protein. A 21 day old sphe-
roid has an average volume of 0.5 µL and contains 21.31 µg
protein. Since 150 spheroids were used in each 10 ml bio-
reactor, 5 mg APAP dissolved directly into 10 mL D-MEM
growth medium at 37 °C (bioreactor volume) provides an equi-
valent dose to the recommended dose in vivo.
The following APAP final concentrations were used: 0, 2.5,
5, 10 and 20 mg APAP per mg cellular protein (referred to as
mg mg−1). For the time-course experiment, mature C3A spher-
oids were treated with repetitive doses of APAP at 0, 48, 96,
144, 192 and 240 h, i.e. providing fresh APAP at the same time
for each medium change. All treatments and controls were per-
formed in duplicate (two 10 ml bioreactors were used for each
treatment point).
Because the plasma half-life of paracetamol is 1.5–2.5 h
(ref. 28) it was decided to collect samples immediately before
and two, four and 24 hours after APAP treatment. Combining
this sampling regimen with the 48 h media-exchange protocol
resulted in samples being collected at 0, 2, 4, 24, 48, 50, 52, 72,
96, 98, 100, 120, 144, 146, 148, 168, 192, 194, 196, 216, 240,
242 and 244 h.
ATP assay
The ATP production rate was used to measure viability of both
control and APAP-treated spheroids as previously described.24
Briefly, spheroids (usually 2 spheroids per sample) were col-
lected at 2, 4, 24, 48, 72, 96, 120, 144, 168, 196, 216 and 240 h.
Cell viability was measured using the Cell-Titer-Glo lumine-
scent cell viability assay (Promega, cat. no. G7571). The experi-
ment was carried out in triplicate. The ATP content of the
spheroids was normalised with reference to a standard curve
for ATP, the untreated control and the amount of cellular
protein present.
Protein determination in spheroids
The amount of protein present in each sample was determined
using the fluorescence-based ProStain Protein Quantification
Kit (Active Motif Inc., cat. no. 15001) as previously described.17
Time-course analysis of global oxidation changes in C3A
spheroids upon APAP treatment
Both reversible and irreversible oxidations were measured
using western blot. Reversible cysteine oxidations, SNO and
SOH were detected after iodoTMT™ zero labelling. Protein
carbonylation was detected after derivatization with 2,4-di-
nitrophenylhydrazine (DNPH).
Each bioreactor vessel contained exactly 150 spheroids. The
treatment dose was 0, 2.5 and 5 mg APAP per mg cellular
protein. 30 spheroids from each treatment group were
sampled at 24, 48, 96 and 144 h, and washed twice with warm
HANKS and once with PBS, allowing the spheroids to sediment
naturally to the bottom of the tube each time. Washed spher-
oids were lysed in a lysis/free-thiol blocking buﬀer containing
150 mM HEPES, pH 7.3, 1 mM EDTA, 0.1 mM neocuproine,
2% SDS, and 50 mM MMTS.
For SNO/SOH analysis all the steps from lysis/blocking until
western blot detection and visualization were performed as
previously described.13 For carbonylation analysis, DNPH deri-
vatisation and detection were performed using the OxyBlot™
kit (Merck Millipore) as previously described.30 Density analy-
sis was performed using Image Studio Lite v. 3.1 (LI-COR Bio-
sciences) as previously described.30 Briefly, the optical density
of each lane was normalised to the averaged total density of all
the lanes on the gel and expressed as percentage of the optical
density. At each treatment time point the data were normalised
to the control. Statistical analysis of the density data was per-
formed using one-way ANOVA (p < 0.05) and the t-test (p <
0.05) built in the Microsoft Excel 2010 package.
IodoTMT™-6plex labelling
The SNO/SOH TMT strategy utilising iodoTMT™-6plex
reagents was used for the analysis of APAP-treated C3A sphe-
roids as previously described.13
6 bioreactors containing 150 spheroids each (approx. 4 mg
protein) were used for experiments. Cells in 3 bioreactors were
Toxicology Research Paper
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treated with 5 mg APAP per mg cellular protein for 48 h and the
other 3 bioreactors were used as control samples (triplicate bio-
logical replicates). After treatment, spheroids were washed twice
with HANKS and once with PBS. Both the control and treated
spheroids were resuspended in lysis/blocking buﬀer and were
lysed by sonication. All the steps from lysis/blocking until anti-
TMT™ enrichment and sample clean up were essentially the
same as previously described.13 Several minor alterations were
applied for improvement. To maximise the eﬃciency of free
thiol blocking, 6 ml of lysis/blocking buﬀer were used for lysis.
The samples were sonicated using 6 rounds of 20 s ON/5 s OFF
at an amplitude of 50% in a tip sonicator (Q500, Qsonica). After
acetone precipitation, protein pellets were washed 4 times with
ice cold acetone before re-suspension in AENS buﬀer (50 mM
AMBI, pH 8, 1 mM EDTA, 0.1 mM neocuproine, 2% SDS) to
maximise removal of unbound MMTS.
nLC MSMS analysis
nLC MSMS data were acquired using Dionex UltiMate® 3000
Rapid Separation UHPLC interfaced via an Easyspray nano-
electrospray source to an Orbitrap Fusion™ Tribrid™ mass
spectrometer (Thermo Scientific). The trapping column was
100 µm ID, 2 cm long, packed with 5 µm reverse phase
C18 material (Reprosil, Dr Maisch, Germany). The analytical
column was a Thermo Scientific Easyspray column of 75 µm
ID, 50 cm long, packed with 2 µm C18 particles. The loading
solvent was 0.1% trifluoroacetic acid (TFA), analytical solvents
A and B were 0.1% formic acid (FA) in water and 0.1% FA in
acetonitrile (ACN). All separations were carried out at 50 °C.
Samples were re-suspended in 1% TFA, 5% DMSO and loaded
onto the trap column at 10 µl min−1 for 5 min. Peptides were
eluted onto and separated over the analytical column with the
linear gradient of solvent B (2–35%) for 90 min. An accelerat-
ing voltage of 2.1 kV was applied for electrospray. The quadru-
pole isolation width was set at 1.6 Da. MS1 scans in the m/z
range 300–1200 were acquired in the Orbitrap with 120 000
resolution at an AGC target of 5E5 and a maximum injection
time of 60 ms. Tandem mass spectra were acquired in top
speed mode with the cycle time set at 3 seconds at a normal-
ised collision energy (NCE) of 38. MS2 spectra were acquired in
the Orbitrap at 30 000 resolution, an AGC target of 2E4 and a
maximum filling time of 65 ms. Dynamic exclusion was set at
45 s. Each biological replicate was analysed with duplicate
injections (technical replicates).
Database search
MS data were searched against the UniProt human proteome
(40 779 entries, July 2, 2014) with common contaminants from
MaxQuant (231 entries) using the Mascot server from within
Proteome Discoverer version 1.4. The following search para-
meters were used: enzyme – trypsin; 2 missed cleavages; pre-
cursor mass tolerance – 10 ppm; and fragment mass tolerance
– 20 mmu; variable modifications were – iodoTMT™ (Cys),
carbamidomethylation (Cys) and oxidation (Met). For each bio-
logical replicate, search results from the 2 technical replicates
were merged together. Duplicate features (peptide sequence +
modification) were removed based on descending ion score
values.
Normalisation and significance analysis of redox proteomics data
Ratios of respective reporter ion intensities (127/126, 129/128
and 131/130) were log 2 transformed and normalised to their
median value. Normalised SNO (129/128) and SOH (131/130)
ratios were corrected by the corresponding ratios of total
cysteines (127/126). Rank-based selection criteria were used to
identify SNO/SOH sites that change significantly between the
control and APAP treatment. The most stringent (rank 1) was a
2 sigma approach, which implies that the changes in indivi-
dual SNO/SOH levels, corrected by changes in protein abun-
dance levels, are more than two times the standard deviation
for the particular modification subset, e.g. SNO. Peptides with
2 sigma values for a minimum of 2 biological replicates were
included in rank 1 group.
Peptides with a SNO and/or SOH fold change equal to or
greater than ±1.5 (log 2 ± 0.585) when observed in at least 2
biological replicates were selected as rank 2 peptides. Rank 2
proteins/peptides were predominantly used as additional evi-
dence to support biological processes revealed by the rank
1 group (2 sigma analysis). Peptides with SNO/SOH quantitat-
ive values from APAP treatment only were selected as candi-
dates for rank 3. Selection required that the respective reporter
ions (129 for SNO and 131 for SOH) were present in at least 2
biological replicates at an intensity ≥1000.
We have quantified 8 iodoTMT™-containing peptides (11
SNO/SOH sites) from 8 proteins which fall in rank 1 (>2 sigma)
for quantitative abundance change between control and APAP-
treated spheroids. For instance, for the fatty acid synthase
(FASN) the SNO levels of C1448 and C1459 were above 2 sigma
in all 3 biological replicates. Rank 2 (>1.5-fold change) selected
41 SNO and/or SOH modified peptides. For one protein (EEF2)
we found a rank 2 peptide additional to those found in the
rank 1 subset. The remaining rank 2 peptides represented a
further 40 modified proteins. Finally, the rank 3 group
included 13 unique iodoTMT™-containing peptides (21 SNO
and/or SOH sites) from 13 proteins. Altogether, we quantified
61 APAP sensitive SNO/SOH proteins.
Modification assignment
Modification (SNO, SOH, SNO + SOH) was considered present
if respective ratios were available for at least 2 of the 3 biologi-
cal replicates.
Label-free quantitative proteomics
A fraction of MMTS-blocked protein samples in AENS, from
each iodoTMT™-6plex experiment, was used for the label-free
analysis. Both the control and APAP treated samples (200 µg
protein per condition) were digested on a filter using sodium
deoxycholate (SDC)31 as previously described.13 After digestion,
peptides were recovered by centrifugation (14 000g, 5 min) and
SDC was removed by precipitation with TFA and phase transfer
into ethyl acetate.32
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nLC MSMS analysis and database search were performed as
for the iodoTMT™-6plex experiment, with few modifications.
For MS2, fragment ions were acquired in the ion trap using a
rapid mode with an AGC target of 5E3 ions, a maximum
injection time of 35 ms and the NCE of 32. In the database
search, fragment mass tolerance was 0.6 Da, cysteine
carbamidomethylation was used as a fixed modification and
methionine oxidation as a variable modification. Quantitative
information from label-free experiments was retrieved from
nLC MSMS data using the chromatographic alignment feature
within Progenesis LC MS (Nonlinear Dynamics) as previously
described.13 Significance analysis was performed using the
ANOVA test built into Progenesis LC MS software. Proteins
with at least 3 quantified peptides and ANOVA significance
value p ≤ 0.01 were considered significant.
Data availability
The mass spectrometry proteomics data have been deposited
in the ProteomeXchange Consortium via the PRIDE partner
repository with the dataset identifier PXD003587.
Functional and gene ontology (GO) analyses
String (Search Tool for the Retrieval of Interacting Genes/Pro-
teins, v. 9.1) was used to generate functional networks of all
the mapped SNO/SOH proteins.33 The following parameters
were used: a confidence score of 0.900, no text mining and no
disconnected proteins. Proteins were manually assigned to bio-
logical processes and/or molecular functions based on UniProt
annotations. Ingenuity® Knowledge Base (v. 21249400) was
used in functional analysis of diﬀerentially expressed proteins
(from label-free analysis) and diﬀerentially regulated SNO/SOH
proteins. A GO enrichment analysis was performed using
GOrilla.34 The reference dataset used consisted of all the pro-
teins identified in label-free proteomics analysis (n = 3). The
significance, p-value threshold was p < 0.001. Reported
p-values are enrichment probability values corrected (multi-
plied) by the number of tested GO terms (7530 for process and
1034 for component analyses).
Results
The major objective of this study was to characterise the cellu-
lar response to APAP treatment using doses comparable to the
recommended doses used in vivo (i.e. therapeutic doses at
which the drug-induced changes are reversible). To do this, we
studied the APAP-induced changes in the redox proteome of
C3A spheroids. This in vitro model has been shown to be
stable (on the basis of gene expression, protein abundance
and physiological performance) over at least 24 days35 and pro-
vides a faithful reflection of in vivo toxicology.24 We measured
simultaneously both the changes in abundance of proteins
and the changes in their SNO/SOH PTMs. The experimental
workflow is illustrated in ESI Fig. S1.†
Time-course experiments measuring cellular ATP levels and
global changes in protein SOH, SNO and carbonylation were
initially performed to establish the optimal treatment con-
ditions to be used in the analysis of the C3A redox proteome.13
Redox balance and cell viability upon APAP treatment
The viability of C3A spheroids following APAP treatment was
measured by ATP production.36 Similar results were obtained
by measuring adenylate kinase (ref. 17 and data not shown).
The in vivo recommended dose of 4 g per day for an adult
corresponds to an in vitro treatment dose of 5 milligrams APAP
per milligram cellular hepatic soluble protein (mg mg−1). The
analysis was therefore performed using 0, 2.5, 5, 10 and 20 mg
APAP per mg. Treatment was carried out every 48 h (Fig. 1a)
and ATP levels were measured every 24 h for 10 days.
For the lower APAP doses (2.5 and 5 mg mg−1), we observed
fluctuations in the ATP levels over time, characterised by slight
drops immediately after treatment followed by recoveries,
showing intensified ATP production from 24 to 48 h after treat-
ment as the cell presumably repairs the damage done (Fig. 1a).
The overall cell viability was not aﬀected throughout the treat-
ment period and ATP levels returned to baseline levels in the
absence of further APAP treatment. Contrary to this, at higher
APAP doses (10 and 20 mg mg−1) ATP production diminished
greatly, indicating the onset of cytotoxicity and lethality. Since
the goal of this study was to focus on the eﬀects of physiologi-
cal doses of APAP, the doses of 10 and 20 mg APAP per mg
cellular protein were excluded from subsequent analyses.
As the next step in defining the optimal conditions for the
study, we analysed the overall redox homeostasis using 2.5 and
5 mg APAP per mg cellular protein at the time points 24, 48,
96 and 144 h. Changes in protein oxidation were monitored by
SNO and SOH TMT western blot (showing reversible protein
oxidation, Fig. 1b and c respectively) and carbonyl western blot
assay (irreversible protein oxidation, Fig. 1d). Our results show
that both doses induce a progressive accumulation of SNO
modification over time, which apparently peaked at about 96 h
(Fig. 1b). This was surprising considering that the biological
half-life of APAP is only 2 h. A similar trend of progressive
accumulation was also observed for SOH (even though the
magnitude of changes was considerably lower). Significant
diﬀerences in SNO levels were detected after 48 h of treatment
with 2.5 and 5 mg of APAP (Fig. 1b). SOH levels also changed
significantly after 144 h of treatment with 2.5 mg APAP and
after 96 h and 144 h in 5 mg of APAP (Fig. 1c). Interestingly, at
2.5 mg mg−1 the accumulation of SOH was lower and the oxi-
dation levels did not appear to saturate, even after 144 h
(Fig. 1c).
The largest, simultaneous increase in SNO and SOH levels
was observed at 96 h after cell treatment with 5 mg APAP per mg
cellular protein. However, at this point, cell activity was already
aﬀected as indicated by the strong increase in ATP production
(Fig. 1a). At 5 mg mg−1 after 48 h there was only a minimal
eﬀect on ATP production and essentially no observed increase
in the irreversible protein carbonylation levels (Fig. 1a and d).
Under these conditions increases in both SNO and SOH levels
were observed. Therefore, this treatment (5 mg APAP per mg cel-
lular proteins for 48 h) was used for all subsequent experiments.
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At that level, 6 consecutive APAP treatments had no eﬀect on
the overall viability of the spheroids during a 10 day treatment
regimen (Fig. 1a).
APAP-induced changes in protein expression
Next we sought to investigate the eﬀect of APAP treatment on
the C3A proteome using label-free quantitative mass spectro-
metry. In total, 2953 proteins were quantified. There was no
significant change in abundance between control and APAP
treatment for the large majority of proteins detected (Fig. 2).
Only 266 proteins (approx. 9%) showed diﬀerential regulation
(n = 3, ANOVA p ≤ 0.01, minimum fold change 1.2). In
response to APAP treatment, 164 proteins increased in abun-
dance, while the remaining 102 decreased in abundance (a list
of all the quantified proteins is provided in ESI Table S1A†).
Ingenuity® Pathway Analysis revealed that the energetic
balance of the cells was significantly aﬀected by APAP treat-
ment as indicated by the increased abundance of enzymes
belonging to the pentose phosphate pathway (ESI Table S1B†).
In addition, there was a significant decrease of several
enzymes belonging to the EIF2 signalling pathway (including 9
ribosomal proteins and 5 translation initiation factors,
suggesting that APAP treatment aﬀected protein synthesis); an
increase in several proteins involved in the NRF2-mediated oxi-
dative stress response pathway and an increase in the abun-
dance of three glutathione S-transferases GSTT1, GSTK1,
Fig. 1 Time-course analysis of protein oxidation changes in C3A spheroids upon APAP treatment. Cell viability was accessed by the ATP production
assay (a). The analysis, for 4 diﬀerent APAP doses, was performed over 10 days with measurements taken every 24 h. Due to the signiﬁcantly
increased cytotoxicity, doses 10 and 20 mg APAP per mg soluble cellular proteins (mg mg−1) were excluded from subsequent analyses of protein
oxidation changes. APAP-induced changes in reversible cysteine modiﬁcations, S-nitrosylation (b) and S-sulfenylation (c) were determined using
iodoTMT™-zero labelling and western blot detection with anti-TMT™ antibody. (d) Protein carbonylation was measured after DNPH derivatisation
and western blot detection with anti-DNPH antibody. Protein oxidation levels were visualised with chemiluminescence and optical density analysis
was performed using Image Studio Lite, v.4.0. Error bars indicate standard error. Signiﬁcant diﬀerences in SNO levels were detected after 48 h treat-
ment with 2.5 and 5 mg of APAP (marked by * in panel b). Levels of SOH were signiﬁcantly changed after 144 h of treatment with 2.5 mg APAP (indi-
cated by * in panel c) and after 96 h and 144 h in 5 mg of APAP concentration (indicated by # in panel c). Statistically signiﬁcant diﬀerences were
calculated using a t-test (p < 0.05, n = 3).
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GSTM3 and the related GGH (1.53, 1.20, 1.49 and 1.32 fold
respectively). The observed protein abundance changes illus-
trate activation of antioxidant machinery and increased energy
production that are both required to neutralise the eﬀects of
APAP treatment.
Redox proteome map of C3A spheroids
Prior to APAP treatment, we had mapped the SNO/SOH post-
translational protein modifications in C3A spheroids.
Altogether, we have identified 887 unique, iodoTMT™ contain-
ing peptides with SNO, SOH or both modifications (listed in
ESI Table S1C†). These peptides correspond to 996 modifi-
cation sites on 569 diﬀerent proteins. The majority of modifi-
cation sites were identified with both SNO and SOH
modifications (Fig. 3a). Concurring with the western blot ana-
lysis, the relative abundance of SNO was on average higher
than that of the corresponding SOH (ESI Fig. S2 and S3†).
The identified SNO/SOH proteins in the C3A proteome
belong to basic molecular pathways, e.g. protein synthesis and
degradation, fatty acid metabolism and glycolysis/gluconeo-
genesis, as illustrated in ESI Fig. S4.†
Taking into account known SNO/SOH modifications from
the curated databases RedoxDB37 and dbSNO,38 our study has
identified 737 SNO and 695 SOH novel sites corresponding to
479 SNO and 453 SOH modified proteins (ESI Fig. S5 and
Table S1D†). Thus, this study is the most comprehensive
inventory of SNO/SOH sites and proteins observed in human
hepatocarcinoma cells to date. These SNO/SOH modified pro-
teins were used as a baseline for APAP treatment studies.
Alterations in SNO and SOH modification levels upon APAP
treatment
Complete quantitative information from SNO/SOH TMT ana-
lysis was used to determine APAP sensitive SNO and/or SOH
sites within oxidised proteins (ESI Table S1E†).
Considering all unique iodoTMT™-containing peptides,
the average SNO occupancy in the control was 1.55% ±0.20
increasing to 2.00% ±0.43 following APAP treatment. For SOH,
the average occupancy in the control was 0.56% ±0.15 and this
was unchanged following APAP treatment (0.57% ±0.16, ESI
Table S1C†). There was no correlation between the changes in
protein modification levels and the percentage of site occu-
pancy (ESI Fig. S6†).
To identify the APAP sensitive sites, we applied rank-based
selection criteria (Fig. 3b and Table 1). ESI Table S1E† contains
an extended version of Table 1; annotated MSMS spectra and
assigned ion series masses of all modified peptides are avail-
able in ESI Fig. S8†.
Fig. 2 A volcano plot representing proteins changed in abundance
after treatment with 5 mg APAP per mg cellular protein for 48 h. The
signiﬁcance cut-oﬀ was set at p < 0.01 (ANOVA test), and the biological
cut-oﬀ was set to a fold change of ±1.2 fold. Colours are used to rep-
resent insigniﬁcant proteins (grey), both biologically and statistically sig-
niﬁcant proteins being up-regulated (red) and down-regulated (green).
Fig. 3 SNO/SOH proteome of C3A spheroids under control and APAP
treatment (5 mg APAP per mg cellular protein for 48 h). (a) Overlap
between SNO (dark grey) and SOH (white) sites identiﬁed in C3A spher-
oids under basal conditions. (b) APAP-sensitive SNO/SOH sites were
selected with rank-based criteria, as deﬁned in the Materials and
methods section.
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Significance analysis revealed that less than 10% of all the
quantified iodoTMT™-containing peptides were diﬀerentially
S-nitrosylated and/or S-sulfenylated as a result of APAP treat-
ment. Gene Ontology (GO) annotation enrichment analysis
strongly points to the cytosol/cytoplasm as the most signifi-
cantly enriched cellular localisation (GO: 0005829; p = 1.09 ×
10−7), while the most heavily overrepresented group was pro-
teins present in extracellular organelles e.g. extracellular mem-
brane vesicles (GO: 0043230; p = 1.64 × 10−27). The latter group
contained liver-specific proteins such as prothrombin (F2),
fibronectin (FN1) and alpha-fetoprotein (AFP). In AFP, 8 SNO/
SOH sites were identified, all of which are canonically involved
in intrinsic disulfide bonds. The primary functional Gene
Ontologies for rank 1 peptides were: RNA and mRNA proces-
sing, protein synthesis, protein folding and traﬃcking, lipid
metabolism and canonical Wnt/β-catenin signalling pathway,
as annotated in UniProt (Table 1).
Protein synthesis was the largest and the most diverse
group aﬀected, comprising 14 proteins (16 SNO/SOH sites).
They covered a range of associated processes from RNA
binding to ribosomal translation, protein folding and trans-
port (Fig. 4a). In particular, the protein translation machinery
was highly represented, containing 10 modified proteins
(Table 1). In general, there was an increase in abundance of
both SNO and SOH. The exceptions were NHP2-like protein 1
(NHP2L1), the cytoplasmic isoleucine–tRNA ligase (IARS) and
the T-complex protein 1 subunit beta (CCT2) for which we
observed a decrease in SOH abundance.
The canonical Wnt/β-catenin signalling pathway was also
highly represented with 7 diﬀerentially modified proteins
Table 1 Functional grouping of proteins containing cysteines modiﬁed by SNO and/or SOH and regulated upon APAP treatment. An extended table
is available in ESI Table S1
UniProt
Accession Protein name (UniProt)
Gene name
(primary)
Primary cellular
location(s)a
SNO/SOH
siteb Rankc SNOd SOHd
RNA and mRNA processing
Q00839 Heterogeneous nuclear ribonucleoprotein U HNRNPU Nucl 607 1 Up
P42704 Leucine-rich PPR motif-containing protein, LRPPRC Nucl/Mito 130 2 Up
Q9GZT3 SRA stem–loop-interacting RNA-binding protein SLIRP Mito 48 2 Up
P55769 NHP2-like protein 1 NHP2L1 Nucleolus 30 2 Down
Protein synthesis
P13639 Elongation factor 2 EEF2 Cyto 290 1 Up
P13639 Elongation factor 2 EEF2 Cyto 369 2 Up
P41250 Glycine–tRNA ligase GARS Cyto/Mito 461 3 Up
P41252 Isoleucine–tRNA ligase IARS Cyto 336 1 Down
P55884 Eukaryotic translation initiation factor 3 subunit B EIF3B Cyto 302 2 Up
P23396 40S ribosomal protein S3 RPS3 Cyto 134 3 Up
P62280 40S ribosomal protein S11 RPS11 Cyto 116 2 Up
P36578 60S ribosomal protein L4 RPL4 Cyto 250 2 Up
P30050 60S ribosomal protein L12 RPL12 Cyto 162 3 Up
P62888 60S ribosomal protein L30 RPL30 Cyto 52 2 Up
Q9Y6G3 39S ribosomal protein L42 MRPL42 Mito 45 2 Down
Protein folding and traﬃcking
Q9Y3B3 Transmembrane emp24 domain-containing protein 7 TMED7 ER/Cyto/Golgi 59; 75 1 Up
P55735 Protein SEC13 homolog SEC13 ER/Cyto/Golgi 234 2 Up
P78371 T-complex protein 1 subunit beta CCT2 Cyto 412 1 Down
P55145 Mesencephalic astrocyte-derived neurotrophic factor MANF Secretory 151 2 Down
Lipid metabolism
P49327 Fatty acid synthase FASN Cyto/Golgi 1448; 1459 1 Up
Q8NBQ5 Estradiol 17-beta-dehydrogenase 11 HSD17B11 Cyto/Secretory 215; 217 1 Up
P14324 Farnesyl pyrophosphate synthase FDPS Cyto/Mito/Nucl 333, 340 3 Up
O95573 Long-chain-fatty-acid–CoA ligase 3 ACSL3 Mito/Perox/ER 450 2 Up
O60488 Long-chain-fatty-acid–CoA ligase 4 ACSL4 Mito/Perox/ER 221 2 Up
P37268 Squalene synthase FDFT1 ER 147 2 Down
WNT signalling
Q9HB71 Calcyclin-binding protein CACYBP Nucl/Cyto 154 2 Up
Q9GZS3 WD repeat-containing protein 61 WDR61 Nucl/Cyto 303 1 Up
P35222 Catenin beta-1 CTNNB1 Cyto/Nucl 520 2 Up
Q86VP6 Cullin-associated NEDD8-dissociated protein 1 CAND1 Cyto/Nucl 237 2 Up
P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1 Cyto 168 2 Up
Q9UK22 F-box only protein 2 FBXO2 Cyto 71 2 Down Down
P63208 S-phase kinase-associated protein 1 SKP1 Cyto 120 2 Down
a Primary cellular location(s) according to UniProt: cyto, cytoplasm or cytosol; nucl, nuclear; mito, mitochondrial; ER, endoplasmic reticulum;
Golgi, golgi apparatus; perox, peroxisome; secretory, secreted, vesicles, extracellular matrix. b SNO/SOH site – amino acid number within the
protein sequence that has been modified by SNO and/or SOH. c Rank – criteria used to select proteins with significant changes in the SNO and/
or SOH modification levels upon APAP treatment were as follows: 1 – peptides with 2 sigma values for a minimum of 2 biological replicates; 2 –
peptides with SNO and/or SOH fold change equal to or beyond ±1.5 (log 2 ± 0.585) if observed in a minimum of 2 biological replicates; 3 –
peptides that contained only reporter ions corresponding to samples treated with APAP, the respective reporter ions (129 for SNO and 131 for
SOH) were present in min. 2 biological replicates at an intensity ≥1000. d SNO and SOH – regulation trend observed in quantitative redox
proteomics experiments for the particular modification type, up/down – modification abundance increased/decreased in cells treated with APAP.
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(Table 1). One of these was from rank 1 (SOH-peptide from
WD repeat-containing protein 61 (WDR61)) while the other 6
proteins were rank 2 selected peptides. Of the latter group, 4
proteins were from the SCF (SKP1-CUL1-F-box protein) E3 ubi-
quitin ligase complex (Fig. 4b).
Six proteins involved in lipid synthesis and metabolism
were also diﬀerentially modified (Table 1). All but one exhibi-
ted a significant increase in SNO/SOH levels upon APAP treat-
ment, and this exception was squalene synthase (FDFT1). Two
of the proteins bearing increased modification levels (FASN
and FDFT1) require NADPH for their function.
In addition to the above functional groups, proteins modi-
fied upon APAP treatment were involved in glycolysis, gluco-
neogenesis, DNA damage and stress response. The list is
provided in ESI Table S1B.†
The levels of SNO and SOH were decreased for 9 and 11 pro-
teins respectively upon APAP treatment (ESI Table S1E†). This
unexpected finding can be explained by the fact that cysteines
oxidised to SNO or SOH can also become further oxidised to
sulfinic (SO2H) and sulfonic acid (SO3H), indicators of severe,
irreversible oxidation of proteins. These modifications cannot
be detected by the SNO/SOH TMT method, but may contribute
to the decreased signal of SNO or SOH.
Cellular location of SNO/SOH modified proteins
In untreated control cells, SNO/SOH modified proteins are
found distributed throughout the cell with no particular locali-
sation being over- or under-represented (according to GO
enrichment analysis, data not shown). However, after APAP
treatment, the majority of proteins that show changes in SNO
and/or SOH levels were found to be localised to the cytoplasm
and endoplasmic reticulum (23 and 5 respectively), mitochon-
dria (7) and nucleus (8) (Table 1). In addition, a number of
diﬀerentially modified proteins were identified as proteins
bound for secretion e.g. estradiol 17-beta-dehydrogenase 11
(HSD17B11). Please see ESI Fig. S7 and Table S1E† for more
details.
Site occupancy
The quantitative information obtained from SNO/SOH TMT
analysis can also be used to estimate the levels of relative
modification site occupancy (the fraction of the residue occu-
pied by the identified modification).13 Such levels are con-
sidered to reflect important biological functions of SNO and
SOH.39 For example, modification site occupancy defines levels
of protection against irreversible oxidation or enzyme activity.11
In our study, site occupancy diﬀers considerably from
protein to protein (a complete list of site occupancy values for
all SNO/SOH proteins is presented in ESI Table S1C†).
In addition to examining the APAP-induced diﬀerentially
modified cysteines, sites exhibiting high site occupancy were
also considered. The cysteine site C880 from POTEJ (POTE
ankyrin domain family member J) was the site with the
highest oxidation occupancy upon APAP treatment for both
modifications: 8.6 ±2.2% was SNO modified and a further
10.6 ±2.4% was SOH modified (Fig. 5a). In other words, almost
a fifth (19.2%) of the C880 site was oxidised. The second most
SNO modified site was C892 of the ribosome binding protein 1
Fig. 4 APAP-sensitive proteins related to protein synthesis (a). Proteins with cysteine SNO/SOH levels changed signiﬁcantly between APAP treat-
ment and control were used to map out the pathway based on manual inspection of UniProt annotations. Proteins are represented by their respect-
ive gene names. Changes in cysteine oxidations are marked with arrows. N – S-nitrosylation, S – S-sulfenylation, ↑ – min. 1.5-fold increase in
abundance, ↓ – min. 1.5 decrease in abundance. I and G are abbreviations of amino acids, isoleucine and glycine respectively. The corresponding
data on protein expression and SNO/SOH modiﬁcation levels are provided in ESI Table S1.† APAP-sensitive proteins from the canonical Wnt/
β-catenin signalling pathway (b). Proteins with cysteine SNO/SOH levels changed signiﬁcantly between APAP treatment and control were used to
map out the pathway based on manual inspection of UniProt annotations. Proteins are represented by their gene names. Changes in cysteine
oxidations are marked with arrows. N – S-nitrosylation, S – S-sulfenylation, ↑ – min. 1.5-fold increase in abundance, ↓ – min. 1.5 decrease in
abundance. Alternative routes of Wnt/β-catenin signal transduction are marked with dashed arrows. Protein names marked with arrows indicate
proteins up (↑) or down (↓) regulated under APAP treatment. SCF – Skp, cullin, F-box containing complex (multiprotein E3 ubiquitin ligase complex);
Ub – ubiquitination; PAF1C – RNA Polymerase-associated factor 1 complex. The corresponding data on protein expression and SNO/SOH modiﬁ-
cation levels are provided in ESI Table S1.†
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(RRBP1, located in the endoplasmic reticulum) with 7.2 ±2.3%
SNO occupancy (Fig. 5b). The third most SNO modified site was
C232 from the cytosolic glucose-6-phosphate dehydrogenase
(G6PD) where 6.6 ±4.8% of the site was modified (Fig. 5c).
Amongst S-sulfenylations, C156 from the secretion-destined
sero transferrin (TF) was the second most modified site with
7.4% ±1.9 SOH (Fig. 5d). The C35 site from the antioxidant
thioredoxin (TXN) was the third most abundant SOH site with
5.2% ±2.1 (Fig. 5e).
Within the top 10 SNO/SOH highest occupancy sites, 3 were
extracellular/secreted proteins, the significance of which is
unclear.
None of the cellular or extracellular proteins, which show
high site occupancy, was diﬀerentially modified upon APAP
treatment, underlining that the changes in SNO/SOH sites
described above were highly specific.
Structural features
We observed that some SNO/SOH modified peptides/proteins
share some specific structural features, which suggests that
the SNO and SOH could dramatically impact the protein’s
function. This included both diﬀerentially modified sites
(APAP sensitive) and sites with the highest occupancy (oxi-
dation susceptible). For instance, metal binding was a property
of 20 of the 61 SNO/SOH containing proteins. In one case, the
actual SNO/SOH cysteine was directly involved in metal ion
coordination (C174 in ADH5 – a GSH-dependent formaldehyde
dehydrogenase). This group of 20 metal binding proteins also
included 5 cases where the modified cysteine participated in
disulfide bond formation and thus may interfere with protein
structural integrity40 (ESI Table S1E†).
Finally, two diﬀerent proteins were observed where the
modified cysteine plays a catalytic role: SNO and SOH modifi-
cations of the active site C248 from thiosulfate sulfurtransfer-
ase (TST) (ProSITE-ProRule annotation) and C35 from
thioredoxin (TXN).41 Interestingly, although SNO and SOH
levels of TXN did not change significantly, both were amongst
those with the highest occupancy (6.1 ±3.6% and 5.2 ±2.1%
respectively).
Discussion
As described in the Introduction, hepatocarcinoma cells grown
in 3D cultures have been shown to structurally, metabolically
and physiologically resemble hepatocytes in the liver (reviewed
in ref. 19, 20 and 23). For this reason, we would postulate that
the response to pharmacological doses of APAP described in
this study should provide a basic description of what occurs
in vivo.
APAP induces mild oxidative stress
In this study, we have used advanced mass spectrometric tech-
niques to quantify global changes in abundance of proteins
and their S-nitrosylation and S-sulfenylation levels in C3A 3D
spheroids after exposure to therapeutic-equivalent doses of
APAP (5 mg APAP per mg total soluble protein) to characterise
the early stage response. C3A spheroids can be repeatedly
treated with this dose regimen without reducing their viability.
Measurements of ATP production illustrated that there was no
significant reduction in ATP levels, suggesting no apparent dis-
turbance of mitochondrial function. There was also no signifi-
cant irreversible protein damage as determined by carbonyl
western blot but we did observe increasing levels of reversible
SNO and SOH modifications (which peaked after about 96 h).
In general, the proteomic data from both protein abun-
dance and oxidative modification levels indicate a significant,
but mild oxidative insult. The distributions of the changes in
Fig. 5 Proteins with the highest observed levels of relative site occu-
pancy for SNO (a, b and c) and SOH (a, d and e) modiﬁcations in cells
treated with APAP (5 mg APAP per mg cellular protein for 48 h). Average
site occupancy values were calculated for min. 2 biological replicates,
error bars correspond to ±standard deviation. Presented are gene
names corresponding to the following proteins: POTEJ – POTE ankyrin
domain family member J; RRBP1 – ribosome-binding protein 1; G6PD –
glucose-6-phosphate 1-dehydrogenase; TF – serotransferrin; TXN –
thioredoxin. The corresponding data for relative SNO SOH site occu-
pancy levels for all sites and proteins identiﬁed in this study are provided
in ESI Table S1C.†
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SNO and SOH modifications were highly specific and occurred
in a number of low abundance proteins. The proteins involved
fit well with existing data describing the eﬀect of APAP on
hepatocytes in vitro and in vivo42–44 and reveal a novel mechan-
ism for signal transduction.
Metabolism of APAP and the source of oxidative stress
The spatial location of proteins showing APAP-induced
changes in SNO and SOH levels showed that many were found
in the endoplasmic reticulum (ER) and the cytoplasm. Fewer
were found in the mitochondria and nuclei and among pro-
teins destined for secretion (Table 1 and ESI Table S1A and
S1E†).
The localisation of modified proteins to the ER and cyto-
plasm is consistent with the observation that P450 cyto-
chromes are a known source of reactive species following APAP
treatment.1,45 The reactive species generated are primarily in
the form of H2O2 and peroxinitrite (ONOO
−) which are both
known to induce SNO/SOH formation.1 The high reactivity and
short half-life of peroxinitrite combined with its limited ability
to diﬀuse across biological membranes46 contribute to its
highly localised impact. In addition to H2O2 and peroxinitrite,
NAPQI is also produced in the ER and is known to play a
central role in APAP-induced hepatotoxicity.2,3,47
In the ER and cytoplasm, changes were seen in both
protein abundance and oxidative modifications. In general,
their abundance was decreased and they were heavily S-nitro-
sylated and/or S-sulfenylated. The ER protein, RRBP1, was the
second most SNO modified protein (Fig. 5b). Additionally, two
proteins directly associated with the ER, TMED7 and SEC13
possessed significantly increased SNO levels under APAP treat-
ment (Table 1).
In the cytoplasm, the abundance of all 13 components of
40S ribosome, that were detected, was reduced on average by
1.25-fold (in a remarkably coordinated manner showing a stan-
dard deviation (SD) of only ±0.05). The same eﬀect was seen
for all of the 17 detected 60S ribosomal proteins (1.26-fold, SD
±0.07). Revealing a hitherto unexpected specificity, com-
ponents of the 40S ribosome were diﬀerentially S-sulfenylated
whereas all the identified proteins associated with the 60S
ribosome were S-nitrosylated (ESI Table S1E†). This specificity
can be extended to the initiation factor EIF3B which binds to
and shows the same SOH modification as the small subunit
whereas the elongation factor EEF2 interacts with both sub-
units and shows both SOH and SNO modifications.
In contrast, the level of SNO modification of the 39S mito-
chondrial ribosomal protein L42 was decreased. Two examples
of mitochondrial proteins which show increased SOH modifi-
cation were the long-chain acyl-CoA synthetases 3 and 4
(Table 1). These are both located in the outer mitochondrial
membrane.
Together, the presence of APAP-inducible SNO/SOH modifi-
cations predominantly at the ER and associated ribosomes
(assigned cytoplasmic location), as well as the apparent lack of
significant oxidation in mitochondria and nuclei, suggests
that, at least at the physiological doses of APAP used here, the
source of the APAP-induced reactive species is located in or
close to the ER.
Recovery of the cellular redox balance
The recovery strategy that the cell appears to use in order to
cope with alterations in the intracellular redox balance is to
redirect its energy utilisation. The changes appear to be orche-
strated by the Nrf2-mediated response pathway to oxidative
damage and the canonical Wnt/β-catenin signalling pathway.
The Nrf2-mediated response
Despite the fact that therapeutically relevant APAP doses were
used, we observed an increase in the abundance of sixteen pro-
teins involved in the Nrf2 mediated response to oxidative
damage, indicating Nrf2 activation (ESI Table S1†).
In the mouse liver, APAP-induced mild oxidative stress
results in the build-up of Nrf2 and its translocation into the
nucleus, where it functions as a transcription factor.48 Once
activated, Nrf2 has been shown to protect against APAP-
induced hepatotoxicity43,49,50 and induce the production of
Mrp3 and Mrp4 transporters, which may expel potentially toxic
chemicals51 and initiate cell regeneration.44
One of the targets of Nrf2, the heterodimer glutamate
cysteine ligase (composed of an enzymatic (GCLC) and a regu-
latory subunit (GCLM)) catalyzes the first and rate-limiting
step in the production of GSH.49 Abundance of both of these
enzymes was slightly increased (GCLC 1.31 and GCLM 1.15-
fold). GSH synthase (GSS) catalyzing the second step was
increased by 1.19-fold. Thus these changes in abundance may
be the result of the protective Nrf2 transcription.50,52
Another enzyme HAGH that catalyzes the hydrolysis of
S-D-lactoylglutathione to form GSH and D-lactic acid was also
increased by 1.36-fold. Increases in GSH levels have been seen
from 8 to 48 hours after acute APAP treatment in mice.53
Despite the increases in protein amounts, none of these GSH
synthesis pathway proteins changed their SNO or SOH modifi-
cation levels, suggesting that their regulation by oxidative
stress occurred by Nrf2 regulating their synthesis.
The reactive APAP metabolite NAPQI can bind to the
cysteine thiol of GSH. This critical mechanism of detoxifica-
tion is mediated at least in part by phase-two metabolic
enzymes of the glutathione S-transferase family4 and can lead
to GSH depletion. The abundances of three glutathione
S-transferases, GSTT1, GSTK1, GSTM3, and the related GGH
were increased (1.53, 1.20, 1.49 and 1.32 fold respectively).
While these changes appear to be modest, previous proteomic
studies have shown that changes like these are typical and that
they can produce significant alterations in cellular structure
and activity.30 In a previous study comparing growth in 2D or
3D culture, we had observed that the protein levels of three
other glutathione S-transferases were also modulated: the
microsomal MGST1 was reduced by 2.4-fold while the cytosolic
GSTK1 and GSTO1 were increased by 1.3 and 2.8-fold respect-
ively, illustrating that the absolute levels of these enzymes are
also culture specific.30
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Wu et al. have demonstrated that Nrf2 can regulate NADPH
generation and consumption,54 thus providing the link to
regulation of the pentose phosphate pathway. There was an
increase in enzymes of the pentose phosphate pathway. The
abundances of most of its enzymes, G6PD, H6PD, PGD,
TALDO1, and PGLS, were increased (1.82, 1.28, 1.26, 1.21 and
1.21-fold change respectively). The only exception was RPIA
(which was reduced by −1.52-fold). G6PD is the key rate limit-
ing enzyme of the pentose phosphate pathway and was the
protein showing the highest increase in abundance. G6PD has
not previously been reported as S-nitrosylated. Its cysteine
C232 was found to be the third most S-nitrosylated site,
although its relative occupancy did not change significantly
between the control and APAP treatment. This might indicate
that for this protein, feedback activation occurs via protein
synthesis and not by modification. Evidence supporting the
importance of the pentose phosphate pathway can also be
found in TALDO1−/− mice developed by inactivation of the
Taldo1 genomic locus.55 These are very sensitive to APAP treat-
ment and exhibit a loss of mitochondrial membrane potential,
reduced ATP/ADP ratio, and reduced β-catenin phosphoryl-
ation and spontaneously develop hepatocellular carcinomas.
All of these features can be reversed by a lifelong treatment
with N-acetylcysteine.56
Processes that require reducing power, e.g. NADPH and/or
ATP, were also aﬀected by mild APAP treatment. Changes in
the SNO/SOH levels in proteins of the fatty acid synthesis/
metabolism were pronounced following APAP treatment. FASN
(the multi-enzyme protein that catalyses fatty acid synthesis)
and FDFT1 (squalene synthase in the cholesterol synthetic
pathway), both requiring NADPH for enzymatic activity, were
diﬀerentially SNO/SOH modified under APAP treatment (5.6
and −1.8 average fold change). Similarly, two ATP driven long-
chain-fatty-acid–CoA ligases (ACSL3 and 4, which convert free
long-chain fatty acids into fatty acyl-CoA esters, and play a key
role in lipid synthesis and fatty acid degradation) showed
increased SOH modification after APAP treatment (2.5 and
1.5-fold). While the eﬀect on enzyme kinetics cannot be
deduced from these studies, it has been shown by several other
groups that mitochondrial β-oxidation of fatty acids is impaired
during APAP toxicity53 and our results would support this.
Administration of carnitine, the carrier of fatty acids, into mito-
chondria provided protection from APAP toxicity, suggesting a
link between fatty acid oxidation and APAP toxicity.57
Wnt/β-catenin signalling is aﬀected by oxidative stress
Here for the first time we report SNO and SOH modifications
of components in the canonical Wnt/β-catenin signalling
pathway. These changes are considered to be the cellular
response to the oxidative insult rather than the primary
‘damage’.
Canonical Wnt/β-catenin signalling has been shown to be
crucial in regulating the establishment of hepatic metabolic
zonation58 as well as hepatoprotection and liver regeneration
after drug-induced liver injury.59,60 PTMs, like phosphorylation
and ubiquitination, have been shown to play an important role
in regulating this pathway.61 In general, an APAP-induced
increase in SNO/SOH was observed in all detected Wnt/
β-catenin pathway-related proteins, with the exception of SKP1
and FBXO2, where levels decrease.
The major targets aﬀected by SNO/SOH were the com-
ponents of the SCF (Skp1/Cul1/F-box) ubiquitin ligase complex
(SKP1, FBOX2, CAND and CACYBP). The SCF complex is a
multicomponent E3 ubiquitin ligase, responsible for polyubi-
quitination and targeting of proteins for proteasomal degra-
dation. While SNO/SOH modification of the SCF complex has
not been described before, other E3 ubiquitin ligases have
been shown to be inhibited by SNO modification.62
Both β-catenin and WDR61 exhibit an unchanged abun-
dance but an increased SOH modification upon APAP treat-
ment. WDR61 is a component of the PAF1 complex, which is
responsible for the activation of transcription of Wnt genes by
RNA polymerase II. The exact role of SNO modification of
WDR61 is yet to be verified. Of importance might be the newly
established link between Wnt signalling and the Nrf2/ARE oxi-
dative stress response.63 A reduction in the binding of Nrf2 to
β-catenin or a reduction in Nrf2 ubiquitination (and hence a
reduction in its proteolytic degradation) could lead to its trans-
location into the nucleus and activation of G6PD and NQO2.
Corroborating this inactivation of β-catenin, we detected
several other β-catenin responsive proteins in reduced abun-
dance e.g. glutamine synthetase (GLUL) and MAPK3 (−2.9 and
−1.2-fold).
Wnt signalling reduced the abundance of several proteins
related to protein synthesis (including six eukaryotic trans-
lation initiation factors) by a factor of about 1.25. EIF3B was
the only initiation factor where the degree of SOH modifi-
cation was increased (1.5-fold).
The observed reduction in protein synthesis was mirrored
by a reduction in all of the detected proteins associated with
nucleolar ribosome assembly (RPS3, NOB1, TSR1, BRIX1 and
DRG1 on average by 1.35-fold) and the reduced abundance of
the ribosomal proteins (by 1.25 fold) noted above.
Given the low abundance of the SNO and SOH modifi-
cations in the cell and their transient nature, we hypothesise
that SNO/SOH modifications of the Wnt/β-catenin pathway
could represent a novel intracrine signalling mechanism. This
mechanism could account for the Wnt/β-catenin-driven induc-
tion of the cytochromes CYP2E1 and CYP1A2 seen in mice64
and primary human hepatocytes65 and for the induction of
liver regeneration seen in mice44,59 and thus provide evidence
for a further protective strategy against APAP-induced acute
liver injury (AILI).
Modified secreted proteins
Intriguingly, we identified a number of SNO/SOH modified
proteins which are destined to be secreted, e.g. MANF and
HSD17B11. Where SNO/SOH proteins enter the extracellular
space, they might spread oxidative damage due to the release
of coordinated transition metals66 or via transnitrosylation.11
Finally, SNO/SOH modified proteins, when present in body
fluids, would be expected to be ‘trapped’ in their modified
Paper Toxicology Research
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format and therefore are potential candidate biomarkers
reflecting acute or chronic use of APAP. They would be detect-
able in plasma, using strategies like SNO/SOH TMT13 or
Quantitative Cysteine Oxidation Analysis by Multiple Reaction
Monitoring (OxMRM).67 Such early stage indicators of revers-
ible hepatic stress could be complementary to existing late
stage markers such as alanine and aspartate aminotrans-
ferases whose presence in plasma is an indicator of irreversible
liver damage.1
Conclusions
This is the first proteome-wide analysis of reversible cysteine
modifications, S-nitrosylation and S-sulfenylation following
APAP treatment. Our study provides the largest collection of
SNO/SOH proteins resolving basal, APAP-susceptible and APAP
sensitive modification sites and suggests that these modifi-
cations provide an additional novel signalling capacity allow-
ing the cell to respond homeostatically to external stimuli like
APAP treatment. By analysing the redox proteome of the
hepatocarcinoma cell line C3A treated with a therapeutically
relevant dose of APAP, we have revealed that the cell responds
to APAP insult using a variety of strategies simultaneously
(summarised in Fig. 6). While the depletion of GSH and the
appearance of NAPQI are well known from acute toxicity
studies, little or nothing is known about the activation of the
pentose phosphate pathway, the general retardation of protein
synthesis, and the molecular events leading to the activation
of the Wnt/β-catenin and Nrf2 signalling pathways.
From these studies it appears that the strategic response of
the cell to APAP-induced generation of reactive species (in or
close to the ER) is the activation of the Wnt/β-catenin and Nrf2
signalling pathways and the disruption of fatty acid meta-
bolism. These signalling pathways coordinate the maintenance
of GSH and NADPH levels by diverting energy resources from
ribosome assembly and protein synthesis to the pentose phos-
phate pathway as an eﬀective measure to restore homeostasis.
Altogether, our results help unify various observations on the
eﬀects of APAP treatment in vitro and in vivo.
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